U.S. Markets closed

Threshold Pharmaceuticals, Inc. (THLD)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.396-0.00 (-1.00%)
At close: 4:00PM EDT
People also watch
SNSSGALEPPHMSNTAARRY

Threshold Pharmaceuticals, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650-474-8200
http://www.thresholdpharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees15

Key Executives

NameTitlePayExercisedAge
Dr. Harold E. Selick Ph.D.Exec. Chairman576.98kN/A63
Dr. Wilfred E. Jaeger M.D.Interim Chief Exec. Officer and Director55kN/A62
Mr. Joel A. Fernandes CPASr. VP of Fin. and Controller281.42kN/A47
Dr. Tillman E. Pearce M.D.Chief Medical Officer406.29kN/A60
Dr. Mark D. Matteucci Ph.D.Chief Scientific OfficerN/AN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic and diagnostic agents that target tumor cells for the treatment of cancer patients in the United States. It is developing evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; and Phase II clinical trials for the treatment of prostate cancer, pancreatic cancer, melanoma, and HPV negative squamous cell cancer of head and neck. The company’s evofosfamide is also involved in the Phase I clinical trials for the treatment of patients with advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced solid tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I/II clinical trials for advanced kidney cancer or liver cancer; and Phase II clinical trials for the treatment of advanced biliary tract cancer. In addition, it engages in developing Tarloxotinib, a hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer, as well as patients with metastatic squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational positron emission tomography imaging agent for hypoxia. The company has a license agreement with Merck KGaA to co-develop and commercialize evofosfamide; Auckland UniServices Ltd. for the development program based on Tarloxotinib; and Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Corporate Governance

Threshold Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.